-- Robert Preidt
WEDNESDAY, June 19 (HealthDay News) -- Could screening for colon
cancer someday be as easy as having a blood test? Researchers say
just such a test is showing early promise in trials.
The screening checks for levels of miR-21 -- a piece of DNA
known as microRNA. Researchers in the gastrointestinal cancer
research lab at the Baylor Research Institute in Dallas studied
several hundred patients with either colorectal polyps
(noncancerous growths that often precede cancer) or full-blown
They found that measuring levels of miR-21 in the blood
accurately spotted up to 92 percent of patients with colorectal
The test also accurately identified up to 82 percent of patients
with advanced colorectal polyps -- growths that put people at high
risk of developing colorectal cancer.
The study was published June 19 in the
Journal of the National Cancer Institute.
"This blood-based test could be transformative in how we screen patients for colorectal cancer; it would save lives and could result in major savings of health care dollars," Dr. Michael Ramsay, president of Baylor Research Institute, said in an institute news release.
Other experts were cautiously optimistic.
"These results are very promising for the future of cancer screening and treatment," said Dr. Jerald Wishner, director of colorectal surgery at Northern Westchester Hospital in Mount Kisco, N.Y.
"Colonoscopy screening is the current gold standard to detect colon cancer. However, less than 50 percent of Americans who should be screened get screened," Wishner said. "The blood test is a less invasive screening method that will eliminate barriers to colonoscopies, including embarrassment and possible discomfort in preparation for the test."
Dr. David Robbins, associate chief of endoscopy at Lenox Hill
Hospital in New York City, agreed that it is "only a matter of time
before we can screen for the most common, and most lethal, cancers
using a simple blood test."
"This well-designed study brings us one step closer to the holy grail of colon cancer eradication by identifying those at high risk for developing colon cancer by measuring a pretty straightforward genetic signature," Robbins said.
According to the American Cancer Society, colon cancer is the
second leading cancer killer, after lung cancer. More than 102,000
new cases of the disease will be diagnosed among Americans this
year, and almost 51,000 people will die from the disease in
The American Cancer Society has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.